Pacira BioSciences, Inc. conducted its fourth quarter and full year 2025 earnings conference call on February 26, 2026. The call featured company executives discussing financial results. Participants included analysts from major financial firms.
Pacira BioSciences, Inc. (PCRX) hosted its Q4 2025 earnings conference call on February 26, 2026, at 4:30 PM EST. The event was recorded, as announced by the operator at the start.
Susan Mesco, Head of Investor Relations, opened the call, welcoming attendees and introducing the discussion on the company's fourth quarter and full year 2025 financial results. Joining her were Frank Lee, Chief Executive Officer and Director; Brendan Teehan, Chief Commercial Officer; and Shawn Cross, Chief Financial Officer. Jonathan Slonin, Chief Medical Officer, was also listed among company participants.
Analysts on the call included Anthea Li from Jefferies LLC, Research Division; Douglas Tsao from H.C. Wainwright & Co, LLC, Research Division; Leszek Sulewski from Truist Securities, Inc., Research Division; John Gionco from Needham & Company, LLC, Research Division; and Hardik Parikh from JPMorgan Chase & Co, Research Division.
Mesco reminded participants that the call would include forward-looking statements under the safe harbor provisions of federal securities laws. She noted that such statements reflect the company's judgment as of that date and may involve risks and uncertainties, potentially causing actual results to differ materially. For risk factors, she directed listeners to the company's SEC filings or the Pacira website.
The call also addressed non-GAAP financial measures, with reconciliations to GAAP available in the news release issued earlier that afternoon. Mesco concluded her remarks by handing over the discussion.